Date: 2015-07-15
Type of information: Series C financing round
Company: Innavirvax (France)
Investors: FCPR CapDecisif 2 (France) G1J Ile-de-France (France) Pradeyrol Development (France) Fa Dièse (France) FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) (France)
Amount: €3.6 Million
Funding type: series C financing round
Planned used: With this additional capital, and the support of Bpifrance (the French innovation agency) for the PROTHEVIH collaborative project being led by InnaVirVax, the company aims to accelerate the development of VAC-3S, which is currently in Phase 2 of clinical trials. Initiated in 2014, the company\'s phase 2a, European, randomized, double-blind and placebo-controlled study has recruited 86 patients living with HIV in 13 clinical centres in France, Germany and in Spain. The primary endpoint of this PROTECT1 study is to evaluate the immune response to the administration of three different doses of VAC-3S, which will be compared in adults living with HIV-1 who are receiving antiretroviral therapy to control their viral load.
Others: * On July 17, 2015, InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic solutions for infectious and major chronic diseases, has announced completion of its third funding round which has raised €3.6 million ($4 Million) from its historical investors. The FCPR CapDecisif 2, G1J Ile-de-France, Pradeyrol Development, Fa Dièse and FRCI (Fonds Régional de Co-Investissement d’Ile-de-France) funds have decided to reinforce their support for, and confidence in, the company.
Therapeutic area: Infectious diseases
